Baird analyst Mark Marcon raised the firm’s price target on AMN Healthcare (AMN) to $23 from $21 and keeps a Neutral rating on the shares. The firm updated its model as it believes the company’s Q1 will benefit from massive strike revenue as a recovery nears.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN: